Toripalimab Versus Placebo Combined with Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma: a Multicenter, Randomized, Placebo-controlled, Double-blind, Phase 3 Trial
Latest Information Update: 18 Aug 2026
At a glance
- Drugs Toripalimab (Primary) ; Cisplatin; Gemcitabine
- Indications Nasopharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms Navigation
Most Recent Events
- 13 Aug 2026 Planned End Date changed from 1 Jan 2032 to 26 Nov 2030.
- 13 Aug 2026 Planned primary completion date changed from 1 Jan 2030 to 26 Nov 2028.
- 13 Aug 2026 Status changed from recruiting to active, no longer recruiting.